The Compound Report is an educational resource. Nothing on this site constitutes medical advice or encourages personal use of any compound. Always consult a qualified healthcare provider.
Educational reference only. Nothing on this page constitutes medical advice or encourages personal use of this compound. Always consult a qualified healthcare provider before any decision involving your health.
TRI
Tesofensine is a drug that works too well for its own regulatory good — producing weight loss that rivals modern GLP-1 medications, while carrying a cardiovascular liability that makes regulators unwilling to approve it without expensive outcomes data that no company has yet funded.
Tesofensine's story begins at NeuroSearch A/S, a Danish biotechnology company specializing in CNS drug discovery, in the early 2000s. The compound (initially coded NS2330) was identified as a potent triple monoamine reuptake inhibitor from the phenyltropane chemical class — a structural family that includes cocaine and several pharmaceutical compounds. NeuroSearch's initial rationale: in Alzheimer's disease, the cholinergic and monoaminergic neurotransmitter systems both decline; enhancing dopamine, serotonin, and norepinephrine neurotransmission simultaneously might provide symptomatic benefit. In Parkinson's disease, dopamine deficiency is the central problem; TRI activity might provide symptomatic relief. Phase 2 trials for both conditions were run. Both failed for their intended neurological purposes.
The weight loss observation during the Parkinson's trial changed everything. Participants with Parkinson's disease receiving tesofensine lost significantly more weight than controls — not because of disease-related changes but as a direct pharmacological effect. NeuroSearch pivoted. The company reasoned: if tesofensine produces weight loss as an incidental effect in a Parkinson's population, what might it do in obesity trials specifically designed to capture this effect? The Lancet 2008 Phase 2b trial answered this question with remarkable clarity: 10.6% net body weight reduction at the 0.5mg dose over 24 weeks — approximately double what sibutramine or rimonabant achieved at the time.
The cardiovascular problem arrived alongside the efficacy data. The 0.5mg dose that produced impressive weight loss also produced a +6.7 bpm mean heart rate increase. The 1.0mg dose (slightly more effective) produced +7.7 bpm and saw 56.2% of subjects with ≥10 bpm HR increases on ECG. In isolation, a 7-8 bpm heart rate increase might be considered acceptable for a highly effective weight loss drug. But the regulatory context had been shaped by sibutramine's history. Sibutramine — a dual NET/SERT inhibitor with similar monoaminergic mechanism — had been approved for obesity and used widely. The SCOUT cardiovascular outcomes trial showed sibutramine increased risk of major cardiovascular events (MI, stroke) in high-risk patients, leading to worldwide market withdrawal in 2010. Tesofensine's heart rate profile immediately evoked the sibutramine comparison in regulatory discussions.
NeuroSearch ran out of funding before completing Phase 3. Multiple pipeline failures across other programs depleted the company's resources. The Phase 3 obesity trial — which would have required cardiovascular outcome data, thousands of patients, years of follow-up, and hundreds of millions of dollars — was never completed. NeuroSearch was restructured; its assets were acquired by Saniona A/S, a spinout from NeuroSearch's founders. Saniona's solution to the regulatory obstacle was creative: rather than try to get tesofensine approved as a standalone (which would require a CVOT showing no cardiovascular risk), they combined it with metoprolol — a β1-selective adrenoceptor blocker that specifically counteracts the heart rate and blood pressure effects while preserving the weight loss — and advanced this combination (Tesomet) as a new development program.
THE CENTRAL TENSION
Tesofensine has the most impressive weight loss efficacy data of any mechanistically novel oral weight loss compound not yet approved by the FDA or EMA. The Lancet 2008 Phase 2b data (10.6% net body weight loss at 0.5mg over 24 weeks) exceeds most approved anti-obesity medications of its era and rivals GLP-1 agents in some head-to-head comparisons. It works through a completely different mechanism from GLP-1 — directly targeting dopamine, norepinephrine, and serotonin reuptake in the brain rather than gut hormones and satiety signaling — offering potential for patients who do not respond to GLP-1 or who prefer an oral mechanism. The cardiovascular liability (7-8 bpm heart rate increase, 1-3 mmHg blood pressure increase) is the sole obstacle between tesofensine and regulatory approval. Saniona's Tesomet combination with metoprolol addresses this pharmacologically; Phase 3 will determine if the market strategy succeeds. Community users are self-administering tesofensine without the metoprolol component that was deemed necessary for regulatory approval — and without cardiovascular monitoring.
Tesofensine is a dopamine, norepinephrine, and serotonin reuptake inhibitor — by pharmacological class, this is a stimulant. The C4 audit covers mood, energy, reward pathway activation, tolerance potential, and dependence risk.
Tesofensine's triple reuptake inhibition produces a behavioral profile that includes stimulant-like properties: increased energy and alertness from NET inhibition; improved mood and motivation from DAT/SERT inhibition; reduced appetite and enhanced satiety; improved focus and mental clarity — reported by users. The dopaminergic component (DAT inhibition) is the most important from a behavioral safety perspective. DAT inhibition is the primary mechanism of cocaine, methylphenidate, and amphetamine. While tesofensine's IC50 at DAT (6.5 nM) is weaker than cocaine's binding affinity, the chronic sustained NET/DAT/SERT inhibition from daily oral dosing creates a persistent elevation in monoaminergic tone.
The preclinical and clinical data on tesofensine's dependence potential is limited but the pharmacological signal warrants careful framing. DAT inhibition is the pharmacological mechanism of the most addictive substances. At the doses used in clinical trials (0.25-1.0mg), tesofensine's DAT blockade was dose-dependent by PET scanning. Whether this degree of DAT blockade produces reinforcing (reward) properties in humans — the signal required for addiction potential — has not been formally characterized in abuse potential studies that were never conducted for tesofensine. In the community context: the stimulant-class behavioral profile (mood elevation, energy, appetite suppression) creates a subjective experience that could be habit-forming through psychological dependence even in the absence of classical pharmacological addiction. Users should be aware that the motivation to continue taking tesofensine may reflect its stimulant-like behavioral effects rather than just its appetite-suppression utility.
Tesofensine elevates dopamine, norepinephrine, and serotonin simultaneously — the same monoaminergic profile as most antidepressants and many mood-stabilizing drugs. The net behavioral effect: improved mood, increased motivation, reduced anhedonia (the feeling of reward from activities and food). Clinical trial participants reported subjective quality of life improvements that were not entirely explained by weight loss. The mood-elevating effects complicate interpretation of weight loss outcomes: do patients lose weight because they eat less, or partly because improved mood leads to better behavioral adherence? The distinction matters for understanding what happens when tesofensine is stopped — weight regain plus mood decline may create psychological distress driving reintroduction.
What happens when tesofensine is discontinued after sustained use? No specific discontinuation study has been published. Based on pharmacological class: sudden cessation of a TRI that has been elevating monoaminergic tone for weeks-months may produce transient monoamine withdrawal symptoms — low mood, fatigue, increased appetite (rebound), difficulty concentrating. These symptoms may drive resumption of use. The weight loss after discontinuation is expected to largely reverse — as with all anti-obesity medications — but the speed and completeness of weight regain for tesofensine are not well-characterized in published data.
Tesofensine simultaneously inhibits three monoamine transporters with the following in vitro potencies: Norepinephrine transporter (NET): IC50 = 1.7 nM — the most potent inhibition. Dopamine transporter (DAT): IC50 = 6.5 nM. Serotonin transporter (SERT): IC50 = 11.0 nM. The major active metabolite M1 (NS2360) is even more potent at all three transporters: NET IC50 = 0.6 nM; DAT IC50 = 3.0 nM; SERT IC50 = 2.0 nM. This means the plasma pharmacological activity is substantially carried by both parent compound and the active metabolite. The NET preferential profile (most potent at NET) is pharmacologically important: norepinephrine reuptake inhibition mediates sympathomimetic effects (heart rate, blood pressure elevation) and contributes to appetite suppression via α1-adrenoceptor signaling.
Tesofensine produces weight loss through at least three distinct mechanisms that each contribute independently. Appetite suppression via α1-adrenoceptor and D1 dopamine pathways: preclinical work by Axel et al. (Neuropsychopharmacology, 2010) characterized the pharmacological basis of tesofensine's hypophagic effect in diet-induced obese rats. Alpha-1-adrenoceptor and D1 receptor antagonists blocked tesofensine's appetite suppression — confirming that the effect operates through indirect adrenergic and dopaminergic signaling rather than direct receptor agonism. This is a central CNS appetite suppression mechanism distinct from GLP-1's peripheral gut hormone pathway. Increased resting metabolic rate: clinical studies documented tesofensine increases resting energy expenditure by 5-10% in overweight subjects — a direct consequence of sympathomimetic activity from NET inhibition driving thermogenesis and metabolic activity. This metabolic rate increase component distinguishes tesofensine from pure appetite suppressants (like GLP-1 agents) and explains why some weight loss is maintained even in the presence of compensatory appetite increase. Reduced food reward: dopamine reuptake inhibition enhances dopaminergic signaling in the mesolimbic reward pathway. The motivational salience of food — the 'wanting' component of food reward — is mediated by dopamine. By enhancing dopaminergic tone, tesofensine reduces the reward value of food, contributing to spontaneous caloric restriction.
The breadth of tesofensine's mechanism may explain why its efficacy exceeds single-mechanism compounds. GLP-1 receptor agonists primarily suppress appetite through incretin signaling, gastric slowing, and hypothalamic satiety circuits — a powerful but single-dimensional approach. Tesofensine addresses appetite suppression via adrenergic circuits, food reward via dopaminergic circuits, and metabolic rate via thermogenic sympathomimetic effects — three independent pathways simultaneously. Sibutramine, a dual NET/SERT inhibitor (not DAT), achieved only about half the weight loss of tesofensine in the same clinical context — suggesting the DAT component (dopamine reuptake) adds a meaningful independent contribution beyond what dual NET/SERT inhibition alone achieves.
Tesofensine's human evidence base is more robust than most research chemicals in this book — it has a published, peer-reviewed Phase 2b RCT in The Lancet. What it lacks is Phase 3 cardiovascular outcome data.
Astrup A, Breum L, Jensen TJ, Kroustrup JP, Larsen TM. (2008, Lancet): randomized, double-blind, placebo-controlled; n=203 obese adults (BMI 28-40); 24 weeks; tesofensine 0.25, 0.5, or 1.0mg/day plus mild hypocaloric diet vs placebo plus diet. PRIMARY ENDPOINT — WEIGHT LOSS: 0.25mg: -6.7% body weight; 0.5mg: -11.3%; 1.0mg: -12.8%; placebo: -2.0%. Net weight loss (active minus placebo): 0.25mg = -4.7%; 0.5mg = -9.2%; 1.0mg = -10.6%. SECONDARY ENDPOINTS: fat mass reduction consistent with weight loss; waist circumference reduction; improvements in fasting lipids and glucose; quality of life improvements. CARDIOVASCULAR: 0.25mg HR: +3.6 bpm; 0.5mg: +6.7 bpm; 1.0mg: +7.7 bpm. BP: 1-3 mmHg increase at 0.5mg; more at 1.0mg. ADVERSE EFFECTS: dry mouth, nausea, constipation, insomnia, headache — consistent with monoaminergic stimulant class. Most common at higher doses. GRADE B: single large multicenter Phase 2b DBRCT; positive efficacy; significant cardiovascular signal; not replicated in an independent Phase 3 program.
After Saniona acquired tesofensine, a Phase 2 study evaluated Tesomet (tesofensine 0.5mg + metoprolol 50mg) in obese patients with type 2 diabetes (NCT02737891). Key findings: Tesomet combination eliminated the heart rate increase seen with tesofensine alone while maintaining similar weight loss efficacy. The beta-blocker metoprolol specifically counteracts the NET inhibition-mediated sympathomimetic heart rate elevation without substantially interfering with the central appetite suppression and dopamine-mediated food reward reduction mechanisms. An additional Phase 2 study in hypothalamic obesity (a severe form of secondary obesity from hypothalamic damage) showed Tesomet produced significant weight reduction in a population where GLP-1 medications typically show limited efficacy — potentially an important niche indication.
Prader-Willi syndrome (PWS) is a rare genetic condition causing hyperphagia (persistent uncontrollable hunger) and obesity driven by hypothalamic dysfunction. Standard GLP-1 medications have variable efficacy in PWS. Tesomet Phase 2 trial in PWS showed significant reduction in hyperphagia scores and body weight. This is a meaningful finding: PWS hyperphagia is driven by neurological dopaminergic and reward dysregulation — exactly the mechanisms tesofensine targets. If Tesomet achieves Phase 3 success in PWS (or hypothalamic obesity), it would have a clear mechanistic advantage over GLP-1 agents in these specific populations.
COFEPRIS (Mexico's FDA equivalent) approved Tesomet (brand name Nupenta, tesofensine 0.5mg/metoprolol 50mg fixed-dose combination) in 2023 for obesity treatment — the only regulatory approval for any tesofensine-containing product worldwide as of 2026. Mexican approval requires a rigorous national review process; this is not the same as FDA or EMA approval, but it represents a national regulatory authority's evaluation that the benefit-risk ratio is acceptable when the metoprolol combination is included. Importantly: the approval is for the combination, not for standalone tesofensine. Community users taking tesofensine without metoprolol are taking a compound that the only approving regulatory body considered safe only in combination with a beta-blocker.
Indication
Grade
Best Evidence
Notes
Obesity (general) — weight loss efficacy
B
Lancet 2008 (n=203, 24 wks, DBRCT); 0.5mg: -11.3% body weight vs -2.0% placebo
Impressive efficacy; single Phase 2b; no Phase 3 CVOT completed
Cardiovascular safety — standalone
C (negative signal)
0.5mg: +6.7 bpm HR; 1.0mg: +7.7 bpm; 56.2% ≥10bpm ECG changes; 1-3 mmHg BP
Regulatory obstacle; mirrors sibutramine profile that led to its withdrawal
Tesomet (TRI + beta-blocker) safety
B
Phase 1 + Phase 2 T2DM studies; HR elevation eliminated by metoprolol; weight loss preserved
Addresses the primary safety concern; Phase 3 ongoing
Hypothalamic obesity
B
Small Phase 2; Tesomet showed significant weight reduction where GLP-1 is often inadequate
Mechanistically compelling niche; small study
Prader-Willi syndrome
B
Phase 2; hyperphagia reduction and weight loss; ongoing development
Mechanistically appropriate (dopamine/reward pathway)
T2D + obesity (Tesomet)
B
Phase 2 TM001; improved glycemia and weight with mitigated CV signal
Active Phase 3 program
No topic in tesofensine pharmacology is more important for understanding its regulatory history and community safety than the cardiovascular signal. Understanding what happened to sibutramine explains why tesofensine's heart rate data matters so much.
Sibutramine (Meridia/Reductil) was a dual NET/SERT inhibitor approved for obesity in the late 1990s. It produced significant weight loss (6-8% body weight reduction), was widely prescribed, and was considered an acceptable-risk medication for many years. The SCOUT (Sibutramine Cardiovascular OUTcomes) trial enrolled over 10,000 high-risk obese patients for a long-term cardiovascular outcomes study. The results showed sibutramine increased the risk of major cardiovascular events — non-fatal myocardial infarction and non-fatal stroke — in high-risk patients. Sibutramine was withdrawn worldwide in 2010. The mechanism: sustained norepinephrine reuptake inhibition raises sympathetic tone chronically — increasing heart rate, blood pressure, and cardiac work, which in cardiovascular-vulnerable patients translates to adverse events. The FDA subsequently adopted a policy requiring cardiovascular outcome trials for all new obesity medications before approval.
TESOFENSINE'S CARDIOVASCULAR PROFILE vs SIBUTRAMINE — THE DIRECT COMPARISON
Sibutramine at 10mg/day: +2-3 mmHg blood pressure, +3-5 bpm heart rate, ~6-8% weight loss. Tesofensine at 0.5mg/day: +1-3 mmHg blood pressure, +6.7 bpm heart rate, ~11% weight loss. The heart rate increase with tesofensine is LARGER than sibutramine at equivalent therapeutic doses. Tesofensine is a TRI (blocks DAT too) while sibutramine was only dual NET/SERT — the additional DAT inhibition contributes to dopaminergic appetite suppression but not to heart rate elevation. Tesofensine produces roughly twice the weight loss of sibutramine but with a larger absolute heart rate increase. Whether this translates to cardiovascular risk in the same way as sibutramine requires a CVOT. Without that data, the regulatory logic is: sibutramine had similar-or-smaller heart rate increases and caused cardiovascular harm → tesofensine with larger heart rate increases must be presumed to carry at least equivalent cardiovascular risk until proven otherwise. Saniona's conclusion was the same, hence Tesomet (tesofensine + metoprolol = heart rate increase eliminated).
The Mexican regulatory approval was specifically for Tesomet — tesofensine + metoprolol as a fixed combination. Community users taking standalone tesofensine are taking the component that was deemed insufficient for regulatory approval without the beta-blocker that makes the cardiovascular profile acceptable. This is not a theoretical concern: the heart rate elevation is real, dose-dependent, and mechanistically driven by NET inhibition — not a random side effect that varies by individual. Every user of standalone tesofensine should expect a 5-10 bpm heart rate elevation at the 0.5mg dose. For individuals with existing cardiovascular disease, hypertension, arrhythmia, or other cardiac conditions: standalone tesofensine represents meaningful cardiovascular risk. Baseline and monitored blood pressure and resting heart rate are the minimum cardiovascular monitoring for any community user.
ABSOLUTE DRUG INTERACTION CONTRAINDICATIONS — READ BEFORE ANY OTHER SECTION
Tesofensine inhibits SERT (serotonin reuptake transporter), NET, and DAT. The serotonin reuptake inhibition creates dangerous additive serotonin toxicity with several drug classes. (1) ALL SSRIs (selective serotonin reuptake inhibitors): fluoxetine, sertraline, escitalopram, paroxetine, citalopram, fluvoxamine — additive SERT inhibition → excess serotonergic tone → serotonin syndrome (agitation, hyperthermia, hyperreflexia, clonus, diarrhea, tachycardia; severe: seizures, rhabdomyolysis, death). (2) ALL SNRIs (serotonin-norepinephrine reuptake inhibitors): venlafaxine, duloxetine, desvenlafaxine — additive SERT + NET inhibition → serotonin syndrome + amplified hypertension. (3) ALL MAO inhibitors: phenelzine, tranylcypromine, isocarboxazid, selegiline, rasagiline, moclobemide — MAOI blocks monoamine degradation; TRI blocks monoamine reuptake; combined: massive serotonin/dopamine/norepinephrine accumulation → hypertensive crisis + serotonin syndrome. LIFE-THREATENING. (4) 9-ME-BC: covered in the previous chapter — 9-ME-BC is a MAOI-A; do not combine with tesofensine. (5) Other TRIs or stimulants: additive cardiovascular and CNS stimulant effects. (6) Triptans: additive serotonergic effects. (7) Tramadol: serotonergic + opioid interaction risk. (8) Sympathomimetics (ephedrine, pseudoephedrine, amphetamines): additive adrenergic effects on heart rate and blood pressure.
The community's most frequent psychiatric medication is SSRIs — prescribed to a large percentage of adults seeking weight management support (depression and obesity are comorbid conditions). Many community members taking tesofensine for weight loss may concurrently be prescribed an SSRI for depression or anxiety. This combination is contraindicated. Tesofensine inhibits SERT with IC50 = 11 nM; SSRIs inhibit SERT by the same mechanism (fluoxetine IC50 = ~15 nM; sertraline IC50 = ~0.3 nM). Combined: cumulative SERT inhibition approaching complete blockade → serotonin accumulates to toxic levels. The risk is not theoretical — serotonin syndrome has been documented with other TRI-SSRI combinations. Tesofensine should not be combined with any SSRI without direct physician supervision in a setting capable of managing serotonin syndrome.
Context
Dose
Frequency
Established Protocol
Evidence Basis
Lancet Phase 2b clinical trial
0.25, 0.5, or 1.0 mg
Once daily
Physician-supervised; DBRCT
Grade B — definitive efficacy data; 24 weeks
Tesomet (Nupenta — Mexico approved)
0.5 mg tesofensine + 50 mg metoprolol (fixed-dose combination)
Once daily
Physician-prescribed; COFEPRIS approved
Grade B — regulatory approval with beta-blocker included
Community standalone tesofensine
0.5 mg (most common); some start at 0.25 mg
Once daily; morning preferred
Research chemical; no physician oversight; no beta-blocker
Grade E for this specific context — same compound as Grade B trials but without supervision or beta-blocker
For any community user of standalone tesofensine: (1) Baseline cardiovascular assessment: resting heart rate; blood pressure (both arms); pulse rate after 5 minutes of standing (orthostatic assessment). Ideally: ECG to establish baseline rhythm and QTc. (2) Ongoing monitoring: check resting HR and BP weekly during the first month; ongoing monthly thereafter. If HR increases by more than 10 bpm from baseline or BP increases by more than 10 mmHg systolic: stop and reassess. (3) Absolute exclusion criteria for community use: history of cardiovascular disease, coronary artery disease, heart failure, arrhythmia, or cerebrovascular disease; hypertension (>140/90 at baseline); history of MI or stroke; family history of sudden cardiac death at age <50. These populations should not use standalone tesofensine — Tesomet under physician supervision is the only potentially acceptable path.
Some community practitioners prescribe tesofensine with separately prescribed metoprolol (25-50mg) to replicate the Tesomet combination — recognizing that standalone tesofensine is not approved and that the heart rate problem is real. This approach aligns with the rationale behind Mexican Tesomet approval and Saniona's development program. If metoprolol is available under physician prescription, the combination is pharmacologically more appropriate than standalone tesofensine. Practical consideration: metoprolol at 25-50mg is a mild antihypertensive beta-blocker with an extremely well-characterized safety profile. The side effects of metoprolol (mild fatigue, slightly reduced exercise heart rate response) are manageable. The combination of tesofensine's efficacy with metoprolol's HR protection represents the most rational community approach to this compound.
Tesofensine and GLP-1 medications (semaglutide, tirzepatide) are the two most efficacious oral/injectable weight loss options available, representing fundamentally different mechanisms. GLP-1 agents: gut hormone mechanism; injectable (or oral semaglutide at high dose); nausea/vomiting prominent side effects; no cardiovascular concern (actually cardioprotective); no serotonin syndrome risk; expensive; increasing availability. Tesofensine: CNS monoamine mechanism; oral; heart rate elevation; serotonin syndrome risk with SSRIs; stimulant-like behavioral profile; research chemical status. Candidate profiles: GLP-1 first-line for most obesity patients (stronger efficacy data, better safety profile, physician-supervised, cardioprotective). Tesofensine may be more relevant for: patients who don't respond to or tolerate GLP-1 medications; patients whose obesity is driven by food reward/dopamine dysregulation; patients seeking oral rather than injectable therapy; Prader-Willi syndrome; hypothalamic obesity (GLP-1 often ineffective here).
Tesofensine is not a peptide. It is a phenyltropane-class synthetic organic small molecule. It has nothing structurally or mechanistically in common with peptides. It is included in this peptide-focused book because of its community use alongside peptides in metabolic optimization protocols. Vendors who market it as 'tesofensine peptide' are incorrect.
Exercise-induced heart rate increases are transient, acute, and occur with simultaneous cardiovascular adaptation (increased cardiac output, vasodilation, improved endothelial function). Tesofensine's heart rate increase is chronic, sustained (present 24 hours/day while the drug is active), and driven by sympathomimetic NET inhibition — a mechanism that caused cardiovascular harm in long-term sibutramine users who had the same profile. The comparison to exercise is pharmacologically invalid. Exercise heart rate is protective; chronic sympathomimetic heart rate elevation from NET inhibition is the mechanism behind sibutramine's cardiovascular risk.
Mexico approved Tesomet — the fixed-dose combination of tesofensine + metoprolol 50mg. The approval was specifically for the combination, not standalone tesofensine, because standalone tesofensine was deemed to have an unacceptable cardiovascular risk profile without the beta-blocker. Community use of standalone tesofensine is not equivalent to taking the approved Mexican product.
Phentermine releases catecholamines (primarily norepinephrine) from nerve terminals — a different mechanism from tesofensine's reuptake inhibition. More importantly, phentermine's chronic cardiovascular effects are generally mild because it primarily releases NE from peripheral sympathetic terminals (peripheral sympathomimetic) rather than central reuptake inhibition affecting all three monoamine systems simultaneously. Tesofensine's simultaneous DAT + NET + SERT inhibition with highly potent NET IC50 (1.7 nM) represents a more powerful and more central monoaminergic intervention than phentermine. They are not equivalent compounds from a cardiovascular risk perspective.
Astrup A, Breum L, Jensen TJ, Kroustrup JP, Larsen TM. (2008). Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet. 372(9653):1906-1913. PMID 19041766. [The definitive Phase 2b efficacy trial; n=203; 24 weeks; 0.5mg = -11.3% body weight; -2.0% placebo; +6.7 bpm HR. The foundational evidence for tesofensine's weight loss efficacy.]
Axel AM, Mikkelsen JD, Hansen HH. (2010). Tesofensine, a novel triple monoamine reuptake inhibitor, induces appetite suppression by indirect stimulation of alpha1 adrenoceptor and dopamine D1 receptor pathways in the diet-induced obese rat. Neuropsychopharmacology. 35(7):1464-1476. PMC3055463. [The foundational preclinical mechanism paper; DIO rat model; α1-adrenoceptor and D1 pathways confirmed as primary appetite suppression pathways; not direct receptor agonism.]
Hauser RA, et al. (2007). PET dopamine transporter occupancy data for tesofensine. ScienceDirect. [DAT occupancy as a function of dose; dose-dependent blockade confirmed by PET imaging — directly relevant to community dosing pharmacology.]
SCOUT trial — Sibutramine Cardiovascular OUTcomes. (2010). Published in NEJM. [The trial that established cardiovascular outcome requirements for obesity drugs; sibutramine's market withdrawal precedent; directly relevant to tesofensine's regulatory challenge.]
Saniona A/S. Tesomet clinical development documents. Phase 1 drug-drug interaction study Q-21125; Phase 2 TM001 (T2DM); heart rate mitigation by metoprolol confirmed. [The technical basis for Tesomet combination; metoprolol prevents HR elevation while preserving weight loss.]
Randomized controlled trial of Tesomet for weight loss in hypothalamic obesity. PMC9175551. [Tesomet in hypothalamic obesity — mechanistically important niche where GLP-1 is often insufficient.]
Tesofensine is a high-efficacy oral weight loss compound with a pharmacological liability that has prevented it from reaching the market — and a creative solution (Tesomet) that may bring it to approval within the next 2-3 years.
The honest summary: tesofensine's weight loss efficacy is genuine, robust, and well-documented. The Lancet 2008 Phase 2b data showing 10.6% net body weight loss at 0.5mg over 24 weeks is not disputed — it is one of the most impressive weight loss efficacy datasets in obesity pharmacology, exceeding most approved agents of its era and comparable to early GLP-1 data. The mechanism (triple reuptake inhibition → appetite suppression + metabolic rate increase + food reward reduction) is pharmacologically sensible and explains the broader efficacy vs single-mechanism compounds. The cardiovascular liability is also genuine, documented, and mechanistically driven: chronic NET inhibition elevates heart rate and blood pressure, and the regulatory shadow of sibutramine's withdrawal makes any new obesity drug with this signal essentially unreviewable without cardiovascular outcomes data. Tesomet's fixed combination with metoprolol is a pharmacologically elegant solution. The Phase 3 program in 2026 will determine whether this solution succeeds.
For community users: standalone tesofensine carries a heart rate elevation that the only approving regulatory body considered insufficient without metoprolol co-administration. The absolute contraindication with SSRIs (extremely common in the target population) creates a real drug interaction risk. Cardiovascular monitoring is non-negotiable. The stimulant-like behavioral profile has potential for psychological dependence. With these caveats properly understood, tesofensine has genuinely compelling evidence behind it — more human efficacy data than most research chemicals in this book — and for specific populations (hypothalamic obesity, Prader-Willi, GLP-1 non-responders) it offers a mechanistic alternative with a different action profile.
— End of Tesofensine —
THE PEPTIDE BIBLE | Tesofensine | For Research & Educational Purposes Only
Tesofensine (NS2330): NOT a peptide — oral synthetic small molecule, phenyltropane chemical class. MW ~336.87 Da. Triple monoamine reuptake inhibitor (TRI). In vitro IC50: NET = 1.7 nM; DAT = 6.5 nM; SERT = 11.0 nM. Active metabolite M1 (NS2360) even more potent. HISTORY: Developed by NeuroSearch (Denmark) for Alzheimer's and Parkinson's — failed those indications; weight loss observed as incidental finding in PD trials; program pivoted to obesity. NeuroSearch went bankrupt before Phase 3. Acquired by Saniona A/S. MECHANISM: NET inhibition → ↑ NE → α1-adrenoceptor appetite suppression + ↑ resting metabolic rate (5-10%); DAT inhibition → ↑ DA → D1 food reward reduction; SERT inhibition → ↑ 5-HT → serotonergic satiety enhancement. Triple mechanism explains superiority vs single-mechanism agents. EFFICACY (Grade B): Lancet 2008 Phase 2b (Astrup et al.); n=203; 24 weeks; DBRCT; 0.5mg = -11.3% body weight vs -2.0% placebo; net -9.2%; improved lipids, waist circumference, quality of life. Approximately 2x weight loss vs sibutramine at same era. CARDIOVASCULAR (Grade C — negative signal): 0.5mg: +6.7 bpm HR; 1.0mg: +7.7 bpm; 56.2% ≥10 bpm HR increase on ECG at 1.0mg; 1-3 mmHg BP increase. SIBUTRAMINE PRECEDENT: sibutramine (dual NET/SERT) withdrawn 2010 after SCOUT trial showed increased cardiovascular events in high-risk patients; tesofensine has larger HR increase than sibutramine; requires CVOT for FDA/EMA approval. TESOMET: Saniona's solution — tesofensine 0.5mg + metoprolol 50mg fixed-dose combination; metoprolol (β1-blocker) eliminates HR elevation while preserving weight loss; Phase 2 confirmed this; COFEPRIS (Mexico) approved Tesomet (brand Nupenta) in 2023 — ONLY regulatory approval; Phase 3 ongoing 2026. DRUG INTERACTIONS (ABSOLUTE CONTRAINDICATIONS): ALL SSRIs, SNRIs (additive SERT inhibition → serotonin syndrome); ALL MAOIs (blocked monoamine degradation + blocked reuptake → hypertensive crisis + serotonin syndrome); 9-ME-BC (MAOI-A → same risk); other stimulants (additive CV effects); triptans; tramadol. C4: stimulant-like behavioral profile; mood elevation, energy increase, food reward reduction; psychological dependence potential; tolerance requires monitoring; withdrawal symptoms possible on discontinuation. CARDIOVASCULAR MONITORING: baseline ECG + HR + BP mandatory; weekly monitoring first month; stop if ≥10 bpm HR increase or ≥10 mmHg SBP increase from baseline. COMMUNITY STANDALONE vs TESOMET: Mexico approved the combination, not standalone; standalone tesofensine = the component regulatory authorities deemed unacceptably risky without metoprolol. WADA: not currently prohibited; stimulant-class under surveillance.
A Structural Modification of Semax With No Published Studies of Its Own. Being Sold as 'The Most Potent Semax Analog.' Every Claim Belongs to Its Parent Compound.
The Compound That Raises NAD+ By Stopping the Body From Destroying It. NNMT: The Enzyme That Wastes Nicotinamide. Fat Loss Without Food Restriction in Mice. The Neelakantan Group's Research Tool Repurposed as a Longevity Drug. Zero Human Trials. 100 mg/Day Community Dose Extrapolated From Mouse IP Injections. The 1-MNA Question: The Metabolite You're Blocking Has Protective Roles in Liver and Kidney. A 2025 Cell/TPS Review Calls for Clinical Translation. Clinics Already Prescribing It Without FDA Ruling on Safety.
Six Human Clinical Trials. 900+ Participants. Safety Indistinguishable From Placebo. Primary Fat Loss Endpoint Failed. WADA Banned. FDA Rejected for Compounding. The Community Uses It Anyway at Doses That Never Worked in the Trials.